The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children
Open accessAbstract
SCOPE Presenting symptoms, distributions and patterns of diseases and vulnerability to invasive aspergillosis (IA) are similar between children and adults. However, differences exist in the epidemiology and underlying conditions, the usefulness of newer diagnostic tools, the pharmacology of antifungal agents and in the evidence from interventional phase III clinical trials. Therefore, the European Society for Clinical Microbiology and Infectious Diseases (ESCMID) and the European Confederation of Medical Mycology (ECMM) have developed a paediatric specific guideline for the diagnosis and management of IA in neonates and children. METHODS Review and discussion of the scientific literature and grading of the available quality of evidence was performed by the paediatric subgroup of the ESCMID-ECMM-European Respiratory Society (ERS) Aspergillus disease guideline working group, which was assigned the mandate for the development of neonatal and paediatric specific recommendations. QUESTIONS Questions addressed by the guideline included the epidemiology of IA in neonates and children; which paediatric patients may benefit from antifungal prophylaxis; how to diagnose IA in neonates and children; which antifungal agents are available for use in neonates and children; which antifungal agents are suitable for prophylaxis and treatment of IA in neonates and children; what is the role of therapeutic drug monitoring of azole antifungals and which management strategies are suitable to be used in paediatric patients. This guideline provides recommendations for the diagnosis, prevention and treatment of IA in the paediatric population, including neonates. The aim of this guideline is to facilitate optimal management of neonates and children at risk for or diagnosed with IA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/588660 · Cited by 4,917
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia
Walsh, T. J., Finberg, R. W., Arndt, C., Hiemenz, J., Schwartz, C., Bodensteiner, D., Pappas, P., Seibel, N., Greenberg, R. N., Dummer, S., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401004 · Cited by 1,205
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
Denning, D. W., Ribaud, P., Milpied, N., Caillot, D., Herbrecht, R., Thiel, E., Haas, A., Ruhnke, M., & Lode, H. (2002) · Clinical Infectious Diseases · doi:10.1086/324620 · Cited by 844
Combination Antifungal Therapy for Invasive Aspergillosis: A Randomized Trial
Marr, K. A., Schlamm, H. T., Herbrecht, R., Rottinghaus, S. T., Bow, E. J., Cornely, O. A., Heinz, W. J., Jagannatha, S., Koh, L. P., Kontoyiannis, D. P., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m13-2508 · Cited by 514
Hope, W. W., Castagnola, E., Groll, A. H., Roilides, E., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., Bassetti, M., Bille, J., Cornely, O. A., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12040 · Cited by 360
Self-citationMenichetti, F., Del Favero, A., Martino, P., Bucaneve, G., Micozzi, A., Girmenia, C., Barbabietola, G., Pagano, L., Leoni, P., Specchia, G., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/515129 · Cited by 244
Caillot, D., Thiébaut, A., Herbrecht, R., de Botton, S., Pigneux, A., Bernard, F., Larché, J., Monchecourt, F., Alfandari, S., & Mahi, L. (2007) · Cancer · doi:10.1002/cncr.23109 · Cited by 190
Herbrecht, R., Maertens, J., Baila, L., Aoun, M., Heinz, W., Martino, R., Schwartz, S., Ullmann, A. J., Meert, L., Paesmans, M., et al. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.334 · Cited by 149
Repeated-Dose Pharmacokinetics of an Oral Solution of Itraconazole in Infants and Children
de Repentigny, L., Ratelle, J., Leclerc, J.-M., Cornu, G., Sokal, E. M., Jacqmin, P., & de Beule, K. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.2.404 · Cited by 142
Cited by
Antifungal Drugs TDM: Trends and Update
Kably, B., Launay, M., Derobertmasure, A., Lefeuvre, S., Dannaoui, E., & Billaud, E. M. (2022) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000952 · Cited by 81
Antifungals in Clinical Use and the Pipeline
Johnson, M. D. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.005 · Cited by 35
Metadata
- Authors
- Warris, A., Lehrnbecher, T., Roilides, E., Castagnola, E., Brüggemann, R. J. M., & Groll, A. H.
- Venue
- Clinical Microbiology and Infection
- Publisher
- Elsevier BV
- Published
- 2019-09
- Volume
- 25
- Issue
- 9
- Pages
- 1096-1113
- ISSN
- 1198-743X (ISSN-L)
- OpenAlex
- W2947835330
- Cited by
- 183
- References
- 16
- FWCI
- 14.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children. https://app.cochat.ai/papers/10.1016/j.cmi.2019.05.019
- The paper
- Warris, A., Lehrnbecher, T., Roilides, E., Castagnola, E., Brüggemann, R. J. M., & Groll, A. H. (2019). ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children. Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2019.05.019
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.